Penile Cancer

8. REFERENCES

1.World Health Organization. Palliative care. 2022. 
https://www.who.int/health-topics/palliative-care

2.Paterson, C., et al. What are the unmet supportive care needs of men affected by penile cancer? A systematic review of the empirical evidence. Eur J Oncol Nurs, 2020. 48: 101805.  
https://www.ncbi.nlm.nih.gov/pubmed/32947156

3.Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008. 336: 924. 
https://www.ncbi.nlm.nih.gov/pubmed/18436948

4.Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995. 
https://www.ncbi.nlm.nih.gov/pubmed/18456631

5.Phillips, B., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 
https://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence.pdf

6.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049. 
https://www.ncbi.nlm.nih.gov/pubmed/18467413

7.WHO Classification of Tumours Editorial Board, Urinary and Male Genital Tumours. WHO Classification of Tumours, 5th Edn. Vol. 8. 2022. 
https://www.iarc.who.int/news-events/who-classification-of-tumours-5th-edition-volume-8-urinary-and-male-genital-tumours/

8.Sanchez, D.F., et al. Pathological factors, behavior, and histological prognostic risk groups in subtypes of penile squamous cell carcinomas (SCC). Semin Diagn Pathol, 2015. 32: 222. 
https://www.ncbi.nlm.nih.gov/pubmed/25677263

9.Thomas, A., et al. Penile cancer. Nat Rev Dis Primers, 2021. 7: 11. 
https://www.ncbi.nlm.nih.gov/pubmed/33574340

10.Fu, L., et al. Global Pattern and Trends in Penile Cancer Incidence: Population-Based Study. JMIR Public Health Surveill, 2022. 8: e34874. 
https://www.ncbi.nlm.nih.gov/pubmed/35793140

11.International Agency for Research on Cancer (IARC). Cancer Today. 2020. 2025. 
https://gco.iarc.fr/today/home

12.Parkin, D.M., et al. Chapter 2: The burden of HPV-related cancers. Vaccine, 2006. 24 Suppl 3: S3/11. 
https://www.ncbi.nlm.nih.gov/pubmed/16949997

13.Cho, S., et al. Twenty-two-year incidence trend of urological cancers in the Republic of Korea: 1999-2020. Investig Clin Urol, 2024. 65: 23. 
https://www.ncbi.nlm.nih.gov/pubmed/38197748

14.Wnetrzak, I., et al. Epidemiology of penile cancer in Poland compared to other European countries. Cancer Med, 2024. 13: e70092. 
https://www.ncbi.nlm.nih.gov/pubmed/39164960

15.Hansen, B.T., et al. Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956-2015. Int J Cancer, 2018. 142: 1586. 
https://www.ncbi.nlm.nih.gov/pubmed/29205336

16.Moen, C.A., et al. Penile Cancers Attributed to Human Papillomavirus Are Associated with Improved Survival for Node-positive Patients. Findings from a Norwegian Cohort Study Spanning 50 Years. Eur Urol Oncol, 2024. 7: 778. 
https://www.ncbi.nlm.nih.gov/pubmed/37949729

17.Moen, C.A., et al. The past, present and future of penile cancer in the Nordic countries. Results from NORDCAN. BJUI Compass, 2025. 6: e70041. 
https://www.ncbi.nlm.nih.gov/pubmed/40584288

18.Boehm, W.U., et al. The Clinical Complexity of Penile Cancer: Current Clinical-Epidemiological Data from the Database of the Free State of Saxony/Germany. Urol Int, 2022. 106: 706. 
https://www.ncbi.nlm.nih.gov/pubmed/34700316

19.Vreeburg, M.T.A., et al. Penile cancer care in the Netherlands: increased incidence, centralisation, and improved survival. BJU Int, 2024. 133: 596. 
https://www.ncbi.nlm.nih.gov/pubmed/38403729

20.Cancer Research UK. Penile Cancer incidence trends over time. 2022. 
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/penile-cancer/incidence#heading-Two

21.Daubisse-Marliac, L., et al. Long-term trends in incidence and survival of penile cancer in France. Cancer Epidemiol, 2017. 50: 125. 
https://www.ncbi.nlm.nih.gov/pubmed/28898817

22.Backes, D.M., et al. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control, 2009. 20: 449. 
https://www.ncbi.nlm.nih.gov/pubmed/19082746

23.Qi, F., et al. Incidence trends and survival outcomes of penile squamous cell carcinoma: evidence from the Surveillance, Epidemiology and End Results population-based data. Ann Transl Med, 2020. 8: 1428. 
https://www.ncbi.nlm.nih.gov/pubmed/33313173

24.Wenzel, M., et al. Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. Cancer Causes Control, 2022. 33: 25. 
https://www.ncbi.nlm.nih.gov/pubmed/34476653

25.Chaux, A., et al. Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World J Urol, 2013. 31: 861. 
https://www.ncbi.nlm.nih.gov/pubmed/22116602

26.Barnholtz-Sloan, J.S., et al. Incidence trends in primary malignant penile cancer. Urol Oncol, 2007. 25: 361. 
https://www.ncbi.nlm.nih.gov/pubmed/17826651

27.Hartwig, S., et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer, 2012. 12: 30. 
https://www.ncbi.nlm.nih.gov/pubmed/22260541

28.Olesen, T.B., et al. Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol, 2019. 20: 145. 
https://www.ncbi.nlm.nih.gov/pubmed/30573285

29.Xu, L., et al. Projected oropharyngeal carcinoma incidence among middle-aged US men. Head Neck, 2019. 41: 3226. 
https://www.ncbi.nlm.nih.gov/pubmed/31125167

30.The Global Cancer Observatory. 26-Penis Fact Sheet. 2022. 
https://gco.iarc.fr/today/data/factsheets/cancers/26-Penis-fact-sheet.pdf

31.Douglawi, A., et al. Updates on the epidemiology and risk factors for penile cancer. Transl Androl Urol, 2017. 6: 785. 
https://www.ncbi.nlm.nih.gov/pubmed/29184774

32.Deng, X., et al. Trends in Incidence, Mortality, and Survival of Penile Cancer in the United States: A Population-Based Study. Front Oncol, 2022. 12: 891623. 
https://www.ncbi.nlm.nih.gov/pubmed/35785206

33.Lebelo, R.L., et al. Diversity of HPV types in cancerous and pre-cancerous penile lesions of South African men: implications for future HPV vaccination strategies. J Med Virol, 2014. 86: 257. 
https://www.ncbi.nlm.nih.gov/pubmed/24155172

34.Stankiewicz, E., et al. HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Mod Pathol, 2009. 22: 1160. 
https://www.ncbi.nlm.nih.gov/pubmed/19465901

35.Kayes, O., et al. Molecular and genetic pathways in penile cancer. Lancet Oncol, 2007. 8: 420. 
https://www.ncbi.nlm.nih.gov/pubmed/17466899

36.Nordenvall, C., et al. Cancer risk among patients with condylomata acuminata. Int J Cancer, 2006. 119: 888. 
https://www.ncbi.nlm.nih.gov/pubmed/16557590

37.Lont, A.P., et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer, 2006. 119: 1078. 
https://www.ncbi.nlm.nih.gov/pubmed/16570278

38.Bezerra, A.L., et al. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer, 2001. 91: 2315. 
https://www.ncbi.nlm.nih.gov/pubmed/11413520

39.Bandini, M., et al. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. Eur Urol Oncol, 2021. 4: 802. 
https://www.ncbi.nlm.nih.gov/pubmed/33199252

40.Holters, S., et al. Challenging the prognostic impact of the new WHO and TNM classifications with special emphasis on HPV status in penile carcinoma. Virchows Arch, 2019. 475: 211. 
https://www.ncbi.nlm.nih.gov/pubmed/30972551

41.Sand, F.L., et al. Prognostic Significance of HPV and p16 Status in Men Diagnosed with Penile Cancer: A Systematic Review and Meta-analysis. Cancer Epidemiol Biomarkers Prev, 2018. 27: 1123. 
https://www.ncbi.nlm.nih.gov/pubmed/29987099

42.Liu, H., et al. Human papillomavirus as a favorable prognostic factor in a subset of head and neck squamous cell carcinomas: A meta-analysis. J Med Virol, 2017. 89: 710. 
https://www.ncbi.nlm.nih.gov/pubmed/27575972

43.Urbute, A., et al. Prognostic Significance of HPV DNA and p16(INK4a) in Anal Cancer: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev, 2020. 29: 703. 
https://www.ncbi.nlm.nih.gov/pubmed/32051192

44.Zhang, J., et al. Prognostic Significance of P16(INK4a) Expression in Penile Squamous Cell Carcinoma: A Meta-Analysis with Trial Sequential Analysis. Biomed Res Int, 2018. 2018: 8345893. 
https://www.ncbi.nlm.nih.gov/pubmed/30105253

45.Chahoud, J., et al. Prognostic Significance of p16 and Its Relationship with Human Papillomavirus Status in Patients with Penile Squamous Cell Carcinoma: Results of 5 Years Follow-Up. Cancers (Basel), 2022. 14. 
https://www.ncbi.nlm.nih.gov/pubmed/36551510

46.Sand, F.L., et al. The prognostic value of p16 and p53 expression for survival after vulvar cancer: A systematic review and meta-analysis. Gynecol Oncol, 2019. 152: 208. 
https://www.ncbi.nlm.nih.gov/pubmed/30415992

47.Mirghani, H., et al. Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: A systematic review. Oral Oncol, 2017. 67: 138. 
https://www.ncbi.nlm.nih.gov/pubmed/28351568

48.de Bruijn, R.E., et al. Patients with penile cancer and the risk of (pre)malignant cervical lesions in female partners: a retrospective cohort analysis. BJU Int, 2013. 112: 905. 
https://www.ncbi.nlm.nih.gov/pubmed/23905914

49.Elst, L., et al. Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization. Eur Urol, 2024. 86: 114. 
https://www.ncbi.nlm.nih.gov/pubmed/38670879

50.Sand, F.L., et al. The prognostic value of p53 and Ki-67 expression status in penile cancer: a systematic review and meta-analysis. Pathology, 2025. 57: 276. 
https://www.ncbi.nlm.nih.gov/pubmed/39939228

51.Chahoud, J., et al. TP53 Mutations Emerge as a Critical Biomarker in Penile Cancer, Superseding Human Papillomavirus Status. Eur Urol, 2024. 86: 128. 
https://www.ncbi.nlm.nih.gov/pubmed/38749849

52.Monteiro, F.S.M., et al. Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study. Oncologist, 2025. 30. 
https://www.ncbi.nlm.nih.gov/pubmed/39222919

53.Li, Y., et al. Impact of TP53 Alterations on Clinical Outcomes in Penile Squamous Cell Carcinoma. Clin Genitourin Cancer, 2025. 23: 102323. 
https://www.ncbi.nlm.nih.gov/pubmed/40240224

54.Nazha, B., et al. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers. Cancer, 2023. 129: 3884. 
https://www.ncbi.nlm.nih.gov/pubmed/37565840

55.Starita, N., et al. Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients. Int J Cancer, 2022. 150: 1879. 
https://www.ncbi.nlm.nih.gov/pubmed/35253909

56.da Silva Santos, R., et al. Hypomethylation at H19DMR in penile squamous cell carcinoma is not related to HPV infection. Epigenetics, 2024. 19: 2305081. 
https://www.ncbi.nlm.nih.gov/pubmed/38245880

57.Ermakov, M.S., et al. Different Mutational Landscapes in Human Papillomavirus-Induced and Human Papillomavirus-Independent Invasive Penile Squamous Cell Cancers. Mod Pathol, 2023. 36: 100250. 
https://www.ncbi.nlm.nih.gov/pubmed/37353203

58.Hrudka, J., et al. Immune cell infiltration, tumour budding, and the p53 expression pattern are important predictors in penile squamous cell carcinoma: a retrospective study of 152 cases. Pathology, 2023. 55: 637. 
https://www.ncbi.nlm.nih.gov/pubmed/37316384

59.Necchi, A., et al. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden. JAMA Netw Open, 2023. 6: e2348002. 
https://www.ncbi.nlm.nih.gov/pubmed/38150257

60.Trias, I., et al. p53 Immunohistochemistry Defines a Subset of Human Papillomavirus-Independent Penile Squamous Cell Carcinomas With Adverse Prognosis. Am J Surg Pathol, 2024. 48: 1439. 
https://www.ncbi.nlm.nih.gov/pubmed/39040011

61.Zhang, J., et al. The efficacy of vaccination to prevent human papilloma viruses infection at anal and oral: a systematic review and meta-analysis. Public Health, 2021. 196: 165. 
https://www.ncbi.nlm.nih.gov/pubmed/34229128

62.Harder, T., et al. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med, 2018. 16: 110. 
https://www.ncbi.nlm.nih.gov/pubmed/30016957

63.Liao, C.I., et al. Trends in Human Papillomavirus-Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017. JAMA Netw Open, 2022. 5: e222530. 
https://www.ncbi.nlm.nih.gov/pubmed/35294540

64.Elst, L., et al. HPV Vaccination: Does It Have a Role in Preventing Penile Cancer and Other Preneoplastic Lesions? Semin Oncol Nurs, 2022. 38: 151284. 
https://www.ncbi.nlm.nih.gov/pubmed/35577640

65.Tsen, H.F., et al. Risk factors for penile cancer: results of a population-based case-control study in Los Angeles County (United States). Cancer Causes Control, 2001. 12: 267. 
https://www.ncbi.nlm.nih.gov/pubmed/11405332

66.Koifman, L., et al. Epidemiological aspects of penile cancer in Rio de Janeiro: evaluation of 230 cases. Int Braz J Urol, 2011. 37: 231. 
https://www.ncbi.nlm.nih.gov/pubmed/21557840

67.Van Howe, R.S., et al. The carcinogenicity of smegma: debunking a myth. J Eur Acad Dermatol Venereol, 2006. 20: 1046. 
https://www.ncbi.nlm.nih.gov/pubmed/16987256

68.Daling, J.R., et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer, 2005. 116: 606. 
https://www.ncbi.nlm.nih.gov/pubmed/15825185

69.Velazquez, E.F., et al. Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Int J Surg Pathol, 2004. 12: 139. 
https://www.ncbi.nlm.nih.gov/pubmed/15173919

70.Velazquez, E.F., et al. Lichen sclerosus in 68 patients with squamous cell carcinoma of the penis: frequent atypias and correlation with special carcinoma variants suggests a precancerous role. Am J Surg Pathol, 2003. 27: 1448. 
https://www.ncbi.nlm.nih.gov/pubmed/14576478

71.Teichman, J.M., et al. Noninfectious penile lesions. Am Fam Physician, 2010. 81: 167. 
https://www.ncbi.nlm.nih.gov/pubmed/20082512

72.Renaud-Vilmer, C., et al. Analysis of alterations adjacent to invasive squamous cell carcinoma of the penis and their relationship with associated carcinoma. J Am Acad Dermatol, 2010. 62: 284. 
https://www.ncbi.nlm.nih.gov/pubmed/20115951

73.Straub Hogan, M.M., et al. Pathological characterization and clinical outcome of penile intraepithelial neoplasia variants: a North American series. Mod Pathol, 2022. 35: 1101. 
https://www.ncbi.nlm.nih.gov/pubmed/35190664

74.Menon, S., et al. International Society of Urological Pathology (ISUP) Multidisciplinary Consensus on Premalignant and Putative Precursor Lesions of Penile Cancer: Working Group 5 report on Terminology, Grading, and Molecular Testing Practices. Am J Surg Pathol, 2025. 
https://www.ncbi.nlm.nih.gov/pubmed/40826809

75.Moch, H., et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2022. 82: 458. 
https://www.ncbi.nlm.nih.gov/pubmed/35853783

76.Chaux, A., et al. Metastatic tumors to the penis: a report of 17 cases and review of the literature. Int J Surg Pathol, 2011. 19: 597. 
https://www.ncbi.nlm.nih.gov/pubmed/20075023

77.Ebel, J.J., et al. Whole-mount evaluation of penectomies for penile cancer: feasibility, cost and comparison to routine sectioning. Histopathology, 2013. 63: 64. 
https://www.ncbi.nlm.nih.gov/pubmed/23738630

78.Corbishley C., et al. Standards and datasets for reporting cancers Dataset for penile and distal urethral cancer histopathology reports. 2022. 
https://www.rcpath.org/uploads/assets/d0e70985-300e-4835-af4583df56025869/Dataset-for-penile-and-distal-urethral-cancer-histopathology-reports.pdf

79.Tang, V., et al. Should centralized histopathological review in penile cancer be the global standard? BJU Int, 2014. 114: 340. 
https://www.ncbi.nlm.nih.gov/pubmed/24053106

80.Vanthoor, J., et al. Making surgery safer by centralization of care: impact of case load in penile cancer. World J Urol, 2020. 38: 1385. 
https://www.ncbi.nlm.nih.gov/pubmed/31292733

81.Aumayr, K., et al. P16INK4A immunohistochemistry for detection of human papilloma virus-associated penile squamous cell carcinoma is superior to in-situ hybridization. Int J Immunopathol Pharmacol, 2013. 26: 611. 
https://www.ncbi.nlm.nih.gov/pubmed/24067458

82.Bezerra, S.M., et al. Human papillomavirus infection and immunohistochemical p16(INK4a) expression as predictors of outcome in penile squamous cell carcinomas. Hum Pathol, 2015. 46: 532. 
https://www.ncbi.nlm.nih.gov/pubmed/25661481

83.Mannweiler, S., et al. Two major pathways of penile carcinogenesis: HPV-induced penile cancers overexpress p16ink4a, HPV-negative cancers associated with dermatoses express p53, but lack p16ink4a overexpression. J Am Acad Dermatol, 2013. 69: 73. 
https://www.ncbi.nlm.nih.gov/pubmed/23474228

84.Corbishley, M.C., et al. Carcinoma of the Penis and Distal Urethra Histopathology Reporting Guide 1st edition. International Collaboration on Cancer Reporting; Sydney, Australia. ISBN: 978-1-925687-05-7. 2017. 
https://www.iccr-cancer.org/datasets/published-datasets/urinary-male-genital/penis/

85.Guimaraes, G.C., et al. Front pattern of invasion in squamous cell carcinoma of the penis: new prognostic factor for predicting risk of lymph node metastases. Urology, 2006. 68: 148. 
https://www.ncbi.nlm.nih.gov/pubmed/16844455

86.Sanchez, D.F., et al. What Is New in the Pathologic Staging of Penile Carcinoma in the 8th Edition of AJCC TNM Model: Rationale for Changes With Practical Stage-by-stage Category Diagnostic Considerations. Adv Anat Pathol, 2021. 28: 209. 
https://www.ncbi.nlm.nih.gov/pubmed/34050061

87.Sali, A.P., et al. Histopathological risk scoring system as a tool for predicting lymph nodal metastasis in penile squamous cell carcinoma. Pathology, 2019. 51: 696. 
https://www.ncbi.nlm.nih.gov/pubmed/31635947

88.Winters, B.R., et al. Predictors of Nodal Upstaging in Clinical Node Negative Patients With Penile Carcinoma: A National Cancer Database Analysis. Urology, 2016. 96: 29. 
https://www.ncbi.nlm.nih.gov/pubmed/27450944

89.Feng, M.A., et al. Concordance of lymphovascular invasion diagnosed in penile carcinoma with and without the immunohistochemical markers ERG and CD31. Histol Histopathol, 2016. 31: 293. 
https://www.ncbi.nlm.nih.gov/pubmed/26452171

90.Dorofte, L., et al. Low level of interobserver concordance in assessing histological subtype and tumor grade in patients with penile cancer may impair patient care. Virchows Arch, 2022. 480: 879. 
https://www.ncbi.nlm.nih.gov/pubmed/34889977

91.Aita, G., et al. Pattern of invasion is the most important prognostic factor in patients with penile cancer submitted to lymph node dissection and pathological absence of lymph node metastasis. BJU Int, 2015. 116: 584. 
https://www.ncbi.nlm.nih.gov/pubmed/25639616

92.Dorofte, L., et al. New histological risk grading system for prediction of lymph node metastasis in patients with penile cancer. Virchows Arch, 2025. 486: 759. 
https://www.ncbi.nlm.nih.gov/pubmed/39251424

93.Cubilla, A.L. The role of pathologic prognostic factors in squamous cell carcinoma of the penis. World J Urol, 2009. 27: 169. 
https://www.ncbi.nlm.nih.gov/pubmed/18766352

94.Zekan, D.S., et al. Prognostic predictors of lymph node metastasis in penile cancer: a systematic review. Int Braz J Urol, 2021. 47: 943. 
https://www.ncbi.nlm.nih.gov/pubmed/33650835

95.Fankhauser, C.D., et al. Lymphovascular and perineural invasion are risk factors for inguinal lymph node metastases in men with T1G2 penile cancer. J Cancer Res Clin Oncol, 2022. 148: 2231. 
https://www.ncbi.nlm.nih.gov/pubmed/35411405

96.Brierley, J., et al., TNM Classification of Malignant Tumours, 9th Edn. 2025. 
http://eu.wiley.com/WileyCDA/WileyTitle/productCd-1444332414.html

97.Li, Z., et al. Corpora Cavernos invasion vs. Corpus Spongiosum invasion in Penile Cancer: A systematic review and meta-analysis. J Cancer, 2021. 12: 1960. 
https://www.ncbi.nlm.nih.gov/pubmed/33753994

98.Sali, A.P., et al. A comparative study of AJCC and the modified staging system in pT2/pT3 penile squamous cell carcinoma - a validation on an external data set. Histopathology, 2022. 80: 566. 
https://www.ncbi.nlm.nih.gov/pubmed/34586682

99.Zhang, Z.L., et al. The importance of extranodal extension in penile cancer: a meta-analysis. BMC Cancer, 2015. 15: 815. 
https://www.ncbi.nlm.nih.gov/pubmed/26510975

100.Gunia, S., et al. Does the width of the surgical margin of safety or premalignant dermatoses at the negative surgical margin affect outcome in surgically treated penile cancer? J Clin Pathol, 2014. 67: 268. 
https://www.ncbi.nlm.nih.gov/pubmed/24100380

101.Wang, J.Y., et al. Prognostic significance of the degree of extranodal extension in patients with penile carcinoma. Asian J Androl, 2014. 16: 437. 
https://www.ncbi.nlm.nih.gov/pubmed/24480925

102.Chaux, A., et al. The prognostic index: a useful pathologic guide for prediction of nodal metastases and survival in penile squamous cell carcinoma. Am J Surg Pathol, 2009. 33: 1049. 
https://www.ncbi.nlm.nih.gov/pubmed/19384188

103.Zito Marino, F., et al. Discrepancy of p16 immunohistochemical expression and HPV RNA in penile cancer. A multiplex in situ hybridization/immunohistochemistry approach study. Infect Agent Cancer, 2021. 16: 22. 
https://www.ncbi.nlm.nih.gov/pubmed/33789689

104.Cubilla, A.L., et al. Value of p16(INK)(4)(a) in the pathology of invasive penile squamous cell carcinomas: A report of 202 cases. Am J Surg Pathol, 2011. 35: 253. 
https://www.ncbi.nlm.nih.gov/pubmed/21263246

105.Canete-Portillo, S., et al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers V: Recommendations on the Use of Immunohistochemical and Molecular Biomarkers in Penile Cancer. Am J Surg Pathol, 2020. 44: e80. 
https://www.ncbi.nlm.nih.gov/pubmed/32235153

106.Amin, M.B., et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 2017. 67: 93. 
https://www.ncbi.nlm.nih.gov/pubmed/28094848

107.Velazquez, E.F., et al. Histologic grade and perineural invasion are more important than tumor thickness as predictor of nodal metastasis in penile squamous cell carcinoma invading 5 to 10 mm. Am J Surg Pathol, 2008. 32: 974. 
https://www.ncbi.nlm.nih.gov/pubmed/18460979

108.Leijte, J.A., et al. Evaluation of current TNM classification of penile carcinoma. J Urol, 2008. 180: 933. 
https://www.ncbi.nlm.nih.gov/pubmed/18635216

109.Sun, M., et al. Development and external validation of a prognostic tool for prediction of cancer-specific mortality after complete loco-regional pathological staging for squamous cell carcinoma of the penis. BJU Int, 2015. 116: 734. 
https://www.ncbi.nlm.nih.gov/pubmed/24552303

110.Li, Z.S., et al. Modification of N staging systems for penile cancer: a more precise prediction of prognosis. Br J Cancer, 2015. 113: 1746. 
https://www.ncbi.nlm.nih.gov/pubmed/26695555

111.Chipollini, J., et al. Patient presentation, differential diagnosis, and management of penile lesions. Can Urol Assoc J, 2019. 13: S2. 
https://www.ncbi.nlm.nih.gov/pubmed/31237837

112.Lont, A.P., et al. A comparison of physical examination and imaging in determining the extent of primary penile carcinoma. BJU Int, 2003. 91: 493. 
https://www.ncbi.nlm.nih.gov/pubmed/12656901

113.Bertolotto, M., et al. Primary and secondary malignancies of the penis: ultrasound features. Abdom Imaging, 2005. 30: 108. 
https://www.ncbi.nlm.nih.gov/pubmed/15759326

114.Kayes, O., et al. The role of magnetic resonance imaging in the local staging of penile cancer. Eur Urol, 2007. 51: 1313. 
https://www.ncbi.nlm.nih.gov/pubmed/17113213

115.Hanchanale, V., et al. The accuracy of magnetic resonance imaging (MRI) in predicting the invasion of the tunica albuginea and the urethra during the primary staging of penile cancer. BJU Int, 2016. 117: 439. 
https://www.ncbi.nlm.nih.gov/pubmed/25600638

116.Krishna, S., et al. Diagnostic Accuracy of MRI in Local Staging (T Category) of Penile Cancer and the Value of Artificial Erection: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol, 2022. 219: 28. 
https://www.ncbi.nlm.nih.gov/pubmed/35195435

117.Bozzini, G., et al. Role of Penile Doppler US in the Preoperative Assessment of Penile Squamous Cell Carcinoma Patients: Results From a Large Prospective Multicenter European Study. Urology, 2016. 90: 131. 
https://www.ncbi.nlm.nih.gov/pubmed/26776562

118.Wood, H.M., et al. Anatomic considerations of the penis, lymphatic drainage, and biopsy of the sentinel node. Urol Clin North Am, 2010. 37: 327. 
https://www.ncbi.nlm.nih.gov/pubmed/20674689

119.Horenblas, S., et al. Squamous cell carcinoma of the penis. IV. Prognostic factors of survival: analysis of tumor, nodes and metastasis classification system. J Urol, 1994. 151: 1239. 
https://www.ncbi.nlm.nih.gov/pubmed/8158767

120.Srinivas, V., et al. Penile cancer: relation of extent of nodal metastasis to survival. J Urol, 1987. 137: 880. 
https://www.ncbi.nlm.nih.gov/pubmed/3573181

121.Kroon, B.K., et al. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol, 2005. 173: 816. 
https://www.ncbi.nlm.nih.gov/pubmed/15711276

122.Horenblas, S., et al. Squamous cell carcinoma of the penis. II. Treatment of the primary tumor. J Urol, 1992. 147: 1533. 
https://www.ncbi.nlm.nih.gov/pubmed/1593683

123.Woldu, S.L., et al. Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. Urol Oncol, 2018. 36: 159 e7. 
https://www.ncbi.nlm.nih.gov/pubmed/29288008

124.Mueller-Lisse, U.G., et al. Functional imaging in penile cancer: PET/computed tomography, MRI, and sentinel lymph node biopsy. Curr Opin Urol, 2008. 18: 105. 
https://www.ncbi.nlm.nih.gov/pubmed/18090498

125.Leijte, J.A., et al. Prospective evaluation of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography in staging clinically node-negative patients with penile carcinoma. BJU Int, 2009. 104: 640. 
https://www.ncbi.nlm.nih.gov/pubmed/19281465

126.Schlenker, B., et al. Detection of inguinal lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT: a prospective single-center study. Urol Oncol, 2012. 30: 55. 
https://www.ncbi.nlm.nih.gov/pubmed/20022269

127.Jakobsen, J.K., et al. DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer. BJU Int, 2021. 127: 254. 
https://www.ncbi.nlm.nih.gov/pubmed/33448605

128.Sadeghi, R., et al. Accuracy of 18F-FDG PET/CT for diagnosing inguinal lymph node involvement in penile squamous cell carcinoma: systematic review and meta-analysis of the literature. Clin Nucl Med, 2012. 37: 436. 
https://www.ncbi.nlm.nih.gov/pubmed/22475891

129.Krishna, R.P., et al. Sonography: an underutilized diagnostic tool in the assessment of metastatic groin nodes. J Clin Ultrasound, 2008. 36: 212. 
https://www.ncbi.nlm.nih.gov/pubmed/17960822

130.Kroon, B.K., et al. Ultrasonography-guided fine-needle aspiration cytology before sentinel node biopsy in patients with penile carcinoma. BJU Int, 2005. 95: 517. 
https://www.ncbi.nlm.nih.gov/pubmed/15705071

131.Lee, E.W.C., et al. High diagnostic accuracy of inguinal ultrasonography and fine-needle aspiration followed by dynamic sentinel lymph node biopsy in men with impalpable and palpable inguinal lymph nodes. BJU Int, 2022. 130: 331. 
https://www.ncbi.nlm.nih.gov/pubmed/35098622

132.Graafland, N.M., et al. Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically node-negative patients. Eur Urol, 2010. 58: 742. 
https://www.ncbi.nlm.nih.gov/pubmed/20800339

133.Catalona, W.J. Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results. J Urol, 1988. 140: 306. 
https://www.ncbi.nlm.nih.gov/pubmed/3398125

134.Protzel, C., et al. Lymphadenectomy in the surgical management of penile cancer. Eur Urol, 2009. 55: 1075. 
https://www.ncbi.nlm.nih.gov/pubmed/19264390

135.d’Ancona, C.A., et al. Long-term followup of penile carcinoma treated with penectomy and bilateral modified inguinal lymphadenectomy. J Urol, 2004. 172: 498. 
https://www.ncbi.nlm.nih.gov/pubmed/15247713

136.Thyavihally, Y.B., et al. Comparative study of perioperative and survival outcomes after video endoscopic inguinal lymphadenectomy (VEIL) and open inguinal lymph node dissection (O-ILND) in the management of inguinal lymph nodes in carcinoma of the penis. J Robot Surg, 2021. 15: 905. 
https://www.ncbi.nlm.nih.gov/pubmed/33484414

137.Wever, L., et al. Incidence and risk factor analysis of complications after sentinel node biopsy for penile cancer. BJU Int, 2022. 130: 486. 
https://www.ncbi.nlm.nih.gov/pubmed/35257463

138.Gopman, J.M., et al. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int, 2015. 116: 196. 
https://www.ncbi.nlm.nih.gov/pubmed/25777366

139.Gomez-Ferrer, A., et al. A single-center comparison of our initial experiences in treating penile and urethral cancer with video-endoscopic inguinal lymphadenectomy (VEIL) and later experiences in melanoma cases. Front Surg, 2022. 9: 870857. 
https://www.ncbi.nlm.nih.gov/pubmed/36225221

140.Munoz Guillermo, V., et al. [Video endoscopic inguinal lymphadenectomy in penile cancer: Systematic review.]. Arch Esp Urol, 2019. 72: 992. 
https://www.ncbi.nlm.nih.gov/pubmed/31823847

141.Horenblas, S., et al. Detection of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node procedure. J Urol, 2000. 163: 100. 
https://www.ncbi.nlm.nih.gov/pubmed/10604324

142.de Vries, H.M., et al. Clinicopathological predictors of finding additional inguinal lymph node metastases in penile cancer patients after positive dynamic sentinel node biopsy: a European multicentre evaluation. BJU Int, 2022. 130: 126. 
https://www.ncbi.nlm.nih.gov/pubmed/34927790

143.Dell’Oglio, P., et al. Hybrid Indocyanine Green-(99m)Tc-nanocolloid for Single-photon Emission Computed Tomography and Combined Radio- and Fluorescence-guided Sentinel Node Biopsy in Penile Cancer: Results of 740 Inguinal Basins Assessed at a Single Institution. Eur Urol, 2020. 78: 865. 
https://www.ncbi.nlm.nih.gov/pubmed/32950298

144.Leijte, J.A., et al. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol, 2007. 52: 170. 
https://www.ncbi.nlm.nih.gov/pubmed/17316967

145.Zou, Z.J., et al. Radiocolloid-based dynamic sentinel lymph node biopsy in penile cancer with clinically negative inguinal lymph node: an updated systematic review and meta-analysis. Int Urol Nephrol, 2016. 48: 2001. 
https://www.ncbi.nlm.nih.gov/pubmed/27577753

146.Hughes, B., et al. Non-invasive and minimally invasive staging of regional lymph nodes in penile cancer. World J Urol, 2009. 27: 197. 
https://www.ncbi.nlm.nih.gov/pubmed/18594830

147.Hovels, A.M., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol, 2008. 63: 387. 
https://www.ncbi.nlm.nih.gov/pubmed/18325358

148.Antoch, G., et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol, 2004. 22: 4357. 
https://www.ncbi.nlm.nih.gov/pubmed/15514377

149.Graafland, N.M., et al. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Eur Urol, 2009. 56: 339. 
https://www.ncbi.nlm.nih.gov/pubmed/19477581

150.Johnstone, P.A.S., et al. Changing Radiotherapy Paradigms in Penile Cancer. Eur Urol Open Sci, 2022. 36: 47. 
https://www.ncbi.nlm.nih.gov/pubmed/35028598

151.Scott, J.G., et al. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. Lancet Oncol, 2021. 22: 1221. 
https://www.ncbi.nlm.nih.gov/pubmed/34363761

152.Sakalis, V.I., et al. What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. Eur Urol Open Sci, 2022. 40: 58. 
https://www.ncbi.nlm.nih.gov/pubmed/35540709

153.Ashley, S., et al. Human Papilloma Virus (HPV) status may impact treatment outcomes in patients with pre-cancerous penile lesions (an eUROGEN Study). Int J Impot Res, 2021. 33: 620. 
https://www.ncbi.nlm.nih.gov/pubmed/32710000

154.Hoekstra, R.J., et al. Penile intraepithelial neoplasia: Nomenclature, incidence and progression to malignancy in the Netherlands. Int J Urol, 2019. 26: 353. 
https://www.ncbi.nlm.nih.gov/pubmed/30508877

155.Kravvas, G., et al. The management of penile intraepithelial neoplasia (PeIN): clinical and histological features and treatment of 345 patients and a review of the literature. J Dermatolog Treat, 2022. 33: 1047. 
https://www.ncbi.nlm.nih.gov/pubmed/32705920

156.Kristiansen, S., et al. Incidence of penile intraepithelial neoplasia and treatment strategies in Sweden 2000-2019. BJU Int, 2022. 129: 752. 
https://www.ncbi.nlm.nih.gov/pubmed/35044047

157.Alnajjar, H.M., et al. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol, 2012. 62: 923. 
https://www.ncbi.nlm.nih.gov/pubmed/22421082

158.Issa, A., et al. Treatment Options and Outcomes for Men with Penile Intraepithelial Neoplasia: A Systematic Review. Eur Urol Focus, 2022. 8: 829. 
https://www.ncbi.nlm.nih.gov/pubmed/33994168

159.Work, G., et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol, 2018. 78: 560. 
https://www.ncbi.nlm.nih.gov/pubmed/29331386

160.Leone, A., et al. Need for Evidence and Consensus on Laser Treatment for Management of Select Primary Penile Tumors. Eur Urol, 2017. 72: 4. 
https://www.ncbi.nlm.nih.gov/pubmed/28131464

161.Shaw, K.S., et al. Combination of imiquimod with cryotherapy in the treatment of penile intraepithelial neoplasia. JAAD Case Rep, 2017. 3: 546. 
https://www.ncbi.nlm.nih.gov/pubmed/29264388

162.Paoli, J., et al. Penile intraepithelial neoplasia: results of photodynamic therapy. Acta Derm Venereol, 2006. 86: 418. 
https://www.ncbi.nlm.nih.gov/pubmed/16955186

163.Schlenker, B., et al. Organ-preserving neodymium-yttrium-aluminium-garnet laser therapy for penile carcinoma: a long-term follow-up. BJU Int, 2010. 106: 786. 
https://www.ncbi.nlm.nih.gov/pubmed/20089106

164.Meijer, R.P., et al. Long-term follow-up after laser therapy for penile carcinoma. Urology, 2007. 69: 759. 
https://www.ncbi.nlm.nih.gov/pubmed/17445665

165.Shabbir, M., et al. Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes. Eur Urol, 2011. 59: 142. 
https://www.ncbi.nlm.nih.gov/pubmed/21050658

166.Caldamone, A.A., et al. Buccal mucosal grafts for urethral reconstruction. Urology, 1998. 51: 15. 
https://www.ncbi.nlm.nih.gov/pubmed/9610551

167.Hakansson, U., et al. Organ-sparing reconstructive surgery in penile cancer: initial experiences at two Swedish referral centres. Scand J Urol, 2015. 49: 149. 
https://www.ncbi.nlm.nih.gov/pubmed/25313620

168.Pang, K.H., et al. Advances in penile-sparing surgical approaches. Asian J Urol, 2022. 9: 359. 
https://www.ncbi.nlm.nih.gov/pubmed/36381598

169.Cakir, O.O., et al. Surgical technique and outcomes following coronal-sparing glans resurfacing for benign and malignant penile lesions. Int J Impot Res, 2022. 34: 495. 
https://www.ncbi.nlm.nih.gov/pubmed/34285385

170.Corbishley, C.M., et al. Glans resurfacing for precancerous and superficially invasive carcinomas of the glans penis: Pathological specimen handling and reporting. Semin Diagn Pathol, 2015. 32: 232. 
https://www.ncbi.nlm.nih.gov/pubmed/25662797

171.Elst, L., et al. Local recurrence after glans-sparing surgery: no impact on penile cancer-specific survival. BJU Int, 2026. 137: 146. 
https://www.ncbi.nlm.nih.gov/pubmed/41178285

172.Roussel, E., et al. Predictors of local recurrence and its impact on survival after glansectomy for penile cancer: time to challenge the dogma? BJU Int, 2021. 127: 606. 
https://www.ncbi.nlm.nih.gov/pubmed/33180969

173.Djajadiningrat, R.S., et al. Penile sparing surgery for penile cancer-does it affect survival? J Urol, 2014. 192: 120. 
https://www.ncbi.nlm.nih.gov/pubmed/24373799

174.Leijte, J.A., et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol, 2008. 54: 161. 
https://www.ncbi.nlm.nih.gov/pubmed/18440124

175.Agrawal, A., et al. The histological extent of the local spread of carcinoma of the penis and its therapeutic implications. BJU Int, 2000. 85: 299. 
https://www.ncbi.nlm.nih.gov/pubmed/10671885

176.Minhas, S., et al. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int, 2005. 96: 1040. 
https://www.ncbi.nlm.nih.gov/pubmed/16225525

177.Philippou, P., et al. Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control. J Urol, 2012. 188: 803. 
https://www.ncbi.nlm.nih.gov/pubmed/22818137

178.Sri, D., et al. A study into the association between local recurrence rates and surgical resection margins in organ-sparing surgery for penile squamous cell cancer. BJU Int, 2018. 122: 576. 
https://www.ncbi.nlm.nih.gov/pubmed/29604228

179.Jazayeri, S.B., et al. Outcomes of PeIN at the surgical margin: insights from an organ-sparing penile cancer database. World J Urol, 2025. 43: 360. 
https://www.ncbi.nlm.nih.gov/pubmed/40478443

180.Lee, E.W.C., et al. Risk of Local Recurrence in Men With Penile Intraepithelial Neoplasia in the Surgical Margin After Penile-sparing Surgery. J Urol, 2023. 210: 778. 
https://www.ncbi.nlm.nih.gov/pubmed/37675864

181.Ellul, T., et al. Frozen section analysis for organ-conserving surgery in penile cancer: Assessing oncological outcomes and trends of local recurrence. Journal of Clinical Urology, 2020. 13: 419. 
https://doi.org/10.1177/2051415820903192

182.Kamel, M.H., et al. Organ Sparing Surgery for Penile Cancer: A Systematic Review. J Urol, 2017. 198: 770. 
https://www.ncbi.nlm.nih.gov/pubmed/28286072

183.Tang, D.H., et al. Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urol Oncol, 2018. 36: 147. 
https://www.ncbi.nlm.nih.gov/pubmed/29097087

184.Musi, G., et al. Thulium-yttrium-aluminium-garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. World J Urol, 2018. 36: 265. 
https://www.ncbi.nlm.nih.gov/pubmed/29197968

185.Falcone, M., et al. Total Glans Resurfacing for the Management of Superficial Penile Cancer: A Retrospective Cohort Analysis in a Tertiary Referral Center. Urology, 2020. 145: 281. 
https://www.ncbi.nlm.nih.gov/pubmed/32683069

186.Perez, J., et al. Oncological and Functional Outcomes After Organ-Sparing Plastic Reconstructive Surgery for Penile Cancer. Urology, 2020. 142: 161. 
https://www.ncbi.nlm.nih.gov/pubmed/32380155

187.O’Kelly, F., et al. A Prospective Study of Total Glans Resurfacing for Localized Penile Cancer to Maximize Oncologic and Functional Outcomes in a Tertiary Referral Network. J Urol, 2017. 197: 1258. 
https://www.ncbi.nlm.nih.gov/pubmed/28027867

188.Pang, K.H., et al. Glansectomy and Reconstruction for Penile Cancer: A Systematic Review. Eur Urol Focus, 2022. 8: 1318. 
https://www.ncbi.nlm.nih.gov/pubmed/34903488

189.Crook, J., et al. Penile brachytherapy: technical aspects and postimplant issues. Brachytherapy, 2010. 9: 151. 
https://www.ncbi.nlm.nih.gov/pubmed/19854685

190.de Crevoisier, R., et al. Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys, 2009. 74: 1150. 
https://www.ncbi.nlm.nih.gov/pubmed/19395183

191.Delaunay, B., et al. Brachytherapy for penile cancer: efficacy and impact on sexual function. Brachytherapy, 2014. 13: 380. 
https://www.ncbi.nlm.nih.gov/pubmed/23896397

192.Kamsu-Kom, L., et al. Clinical Experience with Pulse Dose Rate Brachytherapy for Conservative Treatment of Penile Carcinoma and Comparison with Historical Data of Low Dose Rate Brachytherapy. Clin Oncol (R Coll Radiol), 2015. 27: 387. 
https://www.ncbi.nlm.nih.gov/pubmed/26003455

193.Sharma, D.N., et al. High-dose-rate interstitial brachytherapy for T1-T2-stage penile carcinoma: short-term results. Brachytherapy, 2014. 13: 481. 
https://www.ncbi.nlm.nih.gov/pubmed/25037912

194.Pohankova, D., et al. High-Dose Rate Brachyther-apy in the Treatment of Early Stages of Penile Carcinoma. Klin Onkol, 2019. 32: 52. 
https://www.ncbi.nlm.nih.gov/pubmed/30764630

195.Martz, N., et al. High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis. Clin Transl Radiat Oncol, 2021. 27: 89. 
https://www.ncbi.nlm.nih.gov/pubmed/33537466

196.Kellas-Sleczka, S., et al. Nineteen-year single-center experience in 76 patients with penile cancer treated with high-dose-rate brachytherapy. Brachytherapy, 2019. 18: 493. 
https://www.ncbi.nlm.nih.gov/pubmed/31101437

197.Rouscoff, Y., et al. High-dose rate brachytherapy in localized penile cancer: short-term clinical outcome analysis. Radiat Oncol, 2014. 9: 142. 
https://www.ncbi.nlm.nih.gov/pubmed/24941956

198.Rishi, A., et al. Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer. Brachytherapy, 2022. 21: 839. 
https://www.ncbi.nlm.nih.gov/pubmed/35915039

199.Azrif, M., et al. External-beam radiotherapy in T1-2 N0 penile carcinoma. Clin Oncol (R Coll Radiol), 2006. 18: 320. 
https://www.ncbi.nlm.nih.gov/pubmed/16703750

200.Rozan, R., et al. Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiother Oncol, 1995. 36: 83. 
https://www.ncbi.nlm.nih.gov/pubmed/7501816

201.Delannes, M., et al. Iridium-192 interstitial therapy for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys, 1992. 24: 479. 
https://www.ncbi.nlm.nih.gov/pubmed/1399733

202.Hasan, S., et al. The role of brachytherapy in organ preservation for penile cancer: A meta-analysis and review of the literature. Brachytherapy, 2015. 14: 517. 
https://www.ncbi.nlm.nih.gov/pubmed/25944394

203.Zouhair, A., et al. Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis? Eur J Cancer, 2001. 37: 198. 
https://www.ncbi.nlm.nih.gov/pubmed/11166146

204.Cordoba, A., et al. Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients). Radiat Oncol, 2016. 11: 96. 
https://www.ncbi.nlm.nih.gov/pubmed/27464910

205.Gambachidze, D., et al. Long-term evaluation of urinary, sexual, and quality of life outcomes after brachytherapy for penile carcinoma. Brachytherapy, 2018. 17: 221. 
https://www.ncbi.nlm.nih.gov/pubmed/29089276

206.Djajadiningrat, R.S., et al. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer, 2015. 13: 44. 
https://www.ncbi.nlm.nih.gov/pubmed/25009098

207.Ottenhof, S.R., et al. Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer. Eur Urol Focus, 2019. 5: 867. 
https://www.ncbi.nlm.nih.gov/pubmed/29433986

208.Pagliaro, L.C., et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol, 2010. 28: 3851. 
https://www.ncbi.nlm.nih.gov/pubmed/20625118

209.Pizzocaro, G., et al. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol, 2009. 55: 546. 
https://www.ncbi.nlm.nih.gov/pubmed/18649992

210.Necchi, A., et al. Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clin Genitourin Cancer, 2017. 15: 548. 
https://www.ncbi.nlm.nih.gov/pubmed/28325636

211.Nicolai, N., et al. A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. Clin Genitourin Cancer, 2016. 14: 323. 
https://www.ncbi.nlm.nih.gov/pubmed/26341040

212.Nicholson, S., et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer, 2013. 109: 2554. 
https://www.ncbi.nlm.nih.gov/pubmed/24169355

213.Nicholson, S., et al. VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis. Br J Cancer, 2022. 126: 34. 
https://www.ncbi.nlm.nih.gov/pubmed/34671131

214.Theodore, C., et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol, 2008. 19: 1304. 
https://www.ncbi.nlm.nih.gov/pubmed/18417462

215.Azizi, M., et al. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma? J Urol, 2020. 203: 1147. 
https://www.ncbi.nlm.nih.gov/pubmed/31928407

216.Yi, X.Y., et al. Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence. Asian J Androl, 2022. 24: 180. 
https://www.ncbi.nlm.nih.gov/pubmed/34975068

217.McComas, K., et al. Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. Clin Genitourin Cancer, 2020. 18: e573. 
https://www.ncbi.nlm.nih.gov/pubmed/32335061

218.Ottenhof, S.R., et al. A Prospective Study of Chemoradiotherapy as Primary Treatment in Patients With Locoregionally Advanced Penile Carcinoma. Int J Radiat Oncol Biol Phys, 2023. 117: 139. 
https://www.ncbi.nlm.nih.gov/pubmed/37030606

219.Ottenhof, S.R., et al. Chemoradiation in the treatment of loco-regionally advanced penile cancer. European Urology Supplements, 2019. 18: e655. 
https://www.sciencedirect.com/science/article/pii/S1569905619304841

220.Ornellas, A.A., et al. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol, 2008. 97: 487. 
https://www.ncbi.nlm.nih.gov/pubmed/18425779

221.Veeratterapillay, R., et al. Oncologic Outcomes of Penile Cancer Treatment at a UK Supraregional Center. Urology, 2015. 85: 1097. 
https://www.ncbi.nlm.nih.gov/pubmed/25769781

222.Gotsadze, D., et al. Is conservative organ-sparing treatment of penile carcinoma justified? Eur Urol, 2000. 38: 306. 
https://www.ncbi.nlm.nih.gov/pubmed/10940705

223.Daseler, E.H., et al. Radical excision of the inguinal and iliac lymph glands; a study based upon 450 anatomical dissections and upon supportive clinical observations. Surg Gynecol Obstet, 1948. 87: 679. 
https://www.ncbi.nlm.nih.gov/pubmed/18120502

224.Leijte, J.A., et al. Anatomical mapping of lymphatic drainage in penile carcinoma with SPECT-CT: implications for the extent of inguinal lymph node dissection. Eur Urol, 2008. 54: 885. 
https://www.ncbi.nlm.nih.gov/pubmed/18502024

225.Omorphos, S., et al. Zonal mapping of sentinel lymph nodes in penile cancer patients using fused SPECT/CT imaging and lymphoscintigraphy. Urol Oncol, 2018. 36: 530 e1. 
https://www.ncbi.nlm.nih.gov/pubmed/30318180

226.Yao, K., et al. Lymph Node Mapping in Patients with Penile Cancer Undergoing Pelvic Lymph Node Dissection. J Urol, 2021. 205: 145. 
https://www.ncbi.nlm.nih.gov/pubmed/32755338

227.Culkin, D.J., et al. Advanced penile carcinoma. J Urol, 2003. 170: 359. 
https://www.ncbi.nlm.nih.gov/pubmed/12853775

228.Leewansangtong, S., et al. The risks of lymph node metastasis and the prognostic factors in carcinoma of the penis: analysis of 50 patients treated with bilateral ilioinguinal lymphadenectomy. J Med Assoc Thai, 2001. 84: 204. 
https://www.ncbi.nlm.nih.gov/pubmed/11336079

229.Marconnet, L., et al. Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy. J Urol, 2010. 183: 2227. 
https://www.ncbi.nlm.nih.gov/pubmed/20399455

230.Martin, T.G., et al. Inguinal Lymphadenectomy for Squamous Cell Cancer of the Penis—Experience of a UK Supra-Regional Network. British Journal of Medical and Surgical Urology, 2012. 5: 241. 
https://doi.org/10.1016/j.bjmsu.2011.12.009

231.Joshi, S.S., et al. Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis. JAMA Oncol, 2018. 4: 643. 
https://www.ncbi.nlm.nih.gov/pubmed/29494739

232.Johnson, T.V., et al. Extensive inguinal lymphadenectomy improves overall 5-year survival in penile cancer patients: results from the Surveillance, Epidemiology, and End Results program. Cancer, 2010. 116: 2960. 
https://www.ncbi.nlm.nih.gov/pubmed/20564401

233.Chang, E.K., et al. Underutilization of Surgical Standard of Care for Insured Men with Invasive Penile Cancer. Urol Pract, 2021. 8: 348. 
https://www.ncbi.nlm.nih.gov/pubmed/33898656

234.Cindolo, L., et al. Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World J Urol, 2019. 37: 1649. 
https://www.ncbi.nlm.nih.gov/pubmed/30377813

235.Fankhauser, C.D., et al. Practice Patterns Among Penile Cancer Surgeons Performing Dynamic Sentinel Lymph Node Biopsy and Radical Inguinal Lymph Node Dissection in Men with Penile Cancer: A eUROGEN Survey. Eur Urol Open Sci, 2021. 24: 39. 
https://www.ncbi.nlm.nih.gov/pubmed/34337494

236.Yao, K., et al. Fascia lata preservation during inguinal lymphadenectomy for penile cancer: rationale and outcome. Urology, 2013. 82: 642. 
https://www.ncbi.nlm.nih.gov/pubmed/23876593

237.Schifano, N., et al. Outcomes following radical inguinal lymphadenectomy for penile cancer using a fascial-sparing surgical technique. World J Urol, 2023. 41: 1581. 
https://www.ncbi.nlm.nih.gov/pubmed/37019998

238.Chipollini, J., et al. Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. BJU Int, 2020. 125: 82. 
https://www.ncbi.nlm.nih.gov/pubmed/31356716

239.Li, Z.S., et al. Disease-specific survival after radical lymphadenectomy for penile cancer: prediction by lymph node count and density. Urol Oncol, 2014. 32: 893. 
https://www.ncbi.nlm.nih.gov/pubmed/24994488

240.Mao, W., et al. More lymph node dissection improves survival in patients with newly diagnosed lymph node-positive penile cancer. Int Urol Nephrol, 2019. 51: 641. 
https://www.ncbi.nlm.nih.gov/pubmed/30758771

241.Soodana-Prakash, N., et al. Lymph node yield as a predictor of overall survival following inguinal lymphadenectomy for penile cancer. Urol Oncol, 2018. 36: 471 e19. 
https://www.ncbi.nlm.nih.gov/pubmed/30143385

242.Zhu, Y., et al. Population-based assessment of the number of lymph nodes removed in the treatment of penile squamous cell carcinoma. Urol Int, 2014. 92: 186. 
https://www.ncbi.nlm.nih.gov/pubmed/24246932

243.Johnson, D.E., et al. Management of regional lymph nodes in penile carcinoma. Five-year results following therapeutic groin dissections. Urology, 1984. 24: 308. 
https://www.ncbi.nlm.nih.gov/pubmed/6485188

244.Chipollini, J., et al. Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer. J Urol, 2017. 198: 1346. 
https://www.ncbi.nlm.nih.gov/pubmed/28652123

245.Gulia, A.K., et al. Impact of delay in inguinal lymph node dissection in patients with carcinoma of penis. Indian J Cancer, 2009. 46: 214. 
https://www.ncbi.nlm.nih.gov/pubmed/19574673

246.Hegarty, P.K., et al. Controversies in ilioinguinal lymphadenectomy. Urol Clin North Am, 2010. 37: 421. 
https://www.ncbi.nlm.nih.gov/pubmed/20674697

247.Ravi, R. Morbidity following groin dissection for penile carcinoma. Br J Urol, 1993. 72: 941. 
https://www.ncbi.nlm.nih.gov/pubmed/8306161

248.Koifman, L., et al. Radical open inguinal lymphadenectomy for penile carcinoma: surgical technique, early complications and late outcomes. J Urol, 2013. 190: 2086. 
https://www.ncbi.nlm.nih.gov/pubmed/23770135

249.Stuiver, M.M., et al. Early wound complications after inguinal lymphadenectomy in penile cancer: a historical cohort study and risk-factor analysis. Eur Urol, 2013. 64: 486. 
https://www.ncbi.nlm.nih.gov/pubmed/23490726

250.Sharma, P., et al. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol, 2015. 33: 1585. 
https://www.ncbi.nlm.nih.gov/pubmed/25552207

251.Bevan-Thomas, R., et al. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol, 2002. 167: 1638. 
https://www.ncbi.nlm.nih.gov/pubmed/11912379

252.Bouchot, O., et al. Morbidity of inguinal lymphadenectomy for invasive penile carcinoma. Eur Urol, 2004. 45: 761. 
https://www.ncbi.nlm.nih.gov/pubmed/15149749

253.Mistretta, F.A., et al. Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. Urol Oncol, 2019. 37: 578 e11. 
https://www.ncbi.nlm.nih.gov/pubmed/31296420

254.Nelson, B.A., et al. Complications of inguinal and pelvic lymphadenectomy for squamous cell carcinoma of the penis: a contemporary series. J Urol, 2004. 172: 494. 
https://www.ncbi.nlm.nih.gov/pubmed/15247712

255.Ray, M.D., et al. Minimizing Post-operative Complications of Groin Dissection Using Modified Skin Bridge Technique: A Single-Centre Descriptive Study Showing Post-operative and Early Oncological Outcomes. World J Surg, 2018. 42: 3196. 
https://www.ncbi.nlm.nih.gov/pubmed/29654358

256.Sotelo, R., et al. Complications and adverse events in lymphadenectomy of the inguinal area: worldwide expert consensus. BJS Open, 2024. 8. 
https://www.ncbi.nlm.nih.gov/pubmed/38987232

257.Bertheuil, N., et al. Inguinal lymphadenectomy for stage III melanoma: a comparative study of two surgical approaches at the onset of lymphoedema. Eur J Surg Oncol, 2015. 41: 215. 
https://www.ncbi.nlm.nih.gov/pubmed/25524886

258.Abbas, S., et al. Systematic review and meta-analysis of the used surgical techniques to reduce leg lymphedema following radical inguinal nodes dissection. Surg Oncol, 2011. 20: 88. 
https://www.ncbi.nlm.nih.gov/pubmed/20005090

259.Tonouchi, H., et al. Operative morbidity associated with groin dissections. Surg Today, 2004. 34: 413. 
https://www.ncbi.nlm.nih.gov/pubmed/15108079

260.Schmid, S.C., et al. Final results of the PraVAC trial: prevention of wound complications following inguinal lymph node dissection in patients with penile cancer using epidermal vacuum-assisted wound closure. World J Urol, 2021. 39: 613. 
https://www.ncbi.nlm.nih.gov/pubmed/32372159

261.Tranoulis, A., et al. The Impact of Saphenous Vein Sparing During Inguinal Lymphadenectomy on Postoperative Morbidity in Women With Vulval Cancer: An Updated Per-Groin Meta-analysis of Short-term Outcomes. Int J Gynecol Cancer, 2018. 28: 1232. 
https://www.ncbi.nlm.nih.gov/pubmed/29787421

262.Cui, Y., et al. Saphenous vein sparing during laparoscopic bilateral inguinal lymphadenectomy for penile carcinoma patients. Int Urol Nephrol, 2016. 48: 363. 
https://www.ncbi.nlm.nih.gov/pubmed/26660956

263.Pouwer, A.W., et al. Volume-controlled versus short drainage after inguinofemoral lymphadenectomy in vulvar cancer patients: A Dutch nationwide prospective study. Gynecol Oncol, 2017. 146: 580. 
https://www.ncbi.nlm.nih.gov/pubmed/28687171

264.Weldrick, C., et al. A comparison of fibrin sealant versus standard closure in the reduction of postoperative morbidity after groin dissection: A systematic review and meta-analysis. Eur J Surg Oncol, 2014. 40: 1391. 
https://www.ncbi.nlm.nih.gov/pubmed/25125341

265.Matthey-Gie, M.L., et al. Prospective Randomized Study to Compare Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Therapeutic Lymph Node Dissection With or Without the Use of an Ultrasonic Scalpel. Ann Surg Oncol, 2016. 23: 1716. 
https://www.ncbi.nlm.nih.gov/pubmed/26714939

266.Pouwer, A.W., et al. Reduced morbidity by using LigaSure compared to conventional inguinofemoral lymphadenectomy in vulvar cancer patients: A randomized controlled trial. Surg Oncol, 2020. 35: 149. 
https://www.ncbi.nlm.nih.gov/pubmed/32877884

267.Schwentner, C., et al. Endoscopic inguinofemoral lymphadenectomy--extended follow-up. J Endourol, 2013. 27: 497. 
https://www.ncbi.nlm.nih.gov/pubmed/23067251

268.Kumar, V., et al. Prospective study comparing video-endoscopic radical inguinal lymph node dissection (VEILND) with open radical ILND (OILND) for penile cancer over an 8-year period. BJU Int, 2017. 119: 530. 
https://www.ncbi.nlm.nih.gov/pubmed/27628265

269.Singh, A., et al. Comparing Outcomes of Robotic and Open Inguinal Lymph Node Dissection in Patients with Carcinoma of the Penis. J Urol, 2018. 199: 1518. 
https://www.ncbi.nlm.nih.gov/pubmed/29307685

270.Mosti, G., et al. Compression therapy in lymphedema: Between past and recent scientific data. Phlebology, 2019. 34: 515. 
https://www.ncbi.nlm.nih.gov/pubmed/30626269

271.Ettema, H.B., et al. Prevention of venous thromboembolism in patients with immobilization of the lower extremities: a meta-analysis of randomized controlled trials. J Thromb Haemost, 2008. 6: 1093. 
https://www.ncbi.nlm.nih.gov/pubmed/18429944

272.Lightner, D.J., et al. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. J Urol, 2020. 203: 351. 
https://www.ncbi.nlm.nih.gov/pubmed/31441676

273.Jindal, T., et al. Laparoscopic and robotic video endoscopic inguinal lymphadenectomy by the lateral approach. Asian J Endosc Surg, 2021. 14: 464. 
https://www.ncbi.nlm.nih.gov/pubmed/33200462

274.Yuan, P., et al. Comparative Study of Video Endoscopic Inguinal Lymphadenectomy Through a Hypogastric vs Leg Subcutaneous Approach for Penile Cancer. J Endourol, 2018. 32: 66. 
https://www.ncbi.nlm.nih.gov/pubmed/29256632

275.Subira-Rios, D., et al. Minimally Invasive Laparoscopic Technique for Lymph Node Dissection in Penile Cancer: The Pelvic and Inguinal Single-Site Approach: PISA Technique. Urology, 2021. 153: 351. 
https://www.ncbi.nlm.nih.gov/pubmed/33915082

276.Postlewait, L.M., et al. A Minimally Invasive Approach for Inguinal Lymphadenectomy in Melanoma and Genitourinary Malignancy: Long-Term Outcomes in an Attempted Randomized Control Trial. Ann Surg Oncol, 2017. 24: 3237. 
https://www.ncbi.nlm.nih.gov/pubmed/28770482

277.Fankhauser, C.D., et al. Saphenous-sparing Ascending Video Endoscopic Inguinal Lymph Node Dissection Using a Leg Approach: Surgical Technique and Perioperative and Pathological Outcomes. Eur Urol Open Sci, 2022. 35: 9. 
https://www.ncbi.nlm.nih.gov/pubmed/34825230

278.Wang, S., et al. Comparison of Efficiency of Video Endoscopy and Open Inguinal Lymph Node Dissection. Anticancer Res, 2017. 37: 4623. 
https://www.ncbi.nlm.nih.gov/pubmed/28739762

279.Shao, Y., et al. Comparison of different surgical methods and strategies for inguinal lymph node dissection in patients with penile cancer. Sci Rep, 2022. 12: 2560. 
https://www.ncbi.nlm.nih.gov/pubmed/35169241

280.Tan, Y.G., et al. Comparing the Perioperative and Oncological Outcomes of Open Versus Minimally Invasive Inguinal Lymphadenectomy in Penile Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel), 2025. 17. 
https://www.ncbi.nlm.nih.gov/pubmed/41008879

281.Tang, S., et al. A study protocol for a feasibility randomised controlled trial investigating videoendoscopic radical inguinal lymphadenectomy versus open radical inguinal lymphadenectomy in patients with penile cancer (VELRAD). Pilot Feasibility Stud, 2024. 10: 61. 
https://www.ncbi.nlm.nih.gov/pubmed/38600541

282.Lont, A.P., et al. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol, 2007. 177: 947. 
https://www.ncbi.nlm.nih.gov/pubmed/17296384

283.Liu, J.Y., et al. The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection. World J Urol, 2013. 31: 1519. 
https://www.ncbi.nlm.nih.gov/pubmed/23455885

284.Djajadiningrat, R.S., et al. Prophylactic pelvic lymph node dissection in patients with penile cancer. J Urol, 2015. 193: 1976. 
https://www.ncbi.nlm.nih.gov/pubmed/25498573

285.Lughezzani, G., et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience. J Urol, 2014. 191: 977. 
https://www.ncbi.nlm.nih.gov/pubmed/24262497

286.Zhu, Y., et al. Prospectively packaged ilioinguinal lymphadenectomy for penile cancer: the disseminative pattern of lymph node metastasis. J Urol, 2009. 181: 2103. 
https://www.ncbi.nlm.nih.gov/pubmed/19286211

287.Li, Z.S., et al. Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study. J Cancer Res Clin Oncol, 2017. 143: 329. 
https://www.ncbi.nlm.nih.gov/pubmed/27771796

288.Ottenhof, S.R., et al. F-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography Has High Diagnostic Value for Pelvic and Distant Staging in Patients with High-risk Penile Carcinoma. Eur Urol Focus, 2022. 8: 98. 
https://www.ncbi.nlm.nih.gov/pubmed/33685842

289.Ashwin Sachdeva, et al. Management of Lymph Node-positive Penile Cancer: A Systematic Review. Eur Urol, 2023. 85: 257. 
https://pubmed.ncbi.nlm.nih.gov/37208237/

290.Ravi, R., et al. Role of radiation therapy in the treatment of carcinoma of the penis. Br J Urol, 1994. 74: 646. 
https://www.ncbi.nlm.nih.gov/pubmed/7530129

291.Alnajjar, H.M., et al. Long-term outcomes for penile cancer patients presenting with advanced N3 disease requiring a myocutaneous flap reconstruction or primary closure-a retrospective single centre study. Transl Androl Urol, 2019. 8: S13. 
https://www.ncbi.nlm.nih.gov/pubmed/31143667

292.Koifman, L., et al. The role of primary inguinal surgical debulking for locally advanced penile cancer followed by reconstruction with myocutaneous flap. Int Braz J Urol, 2021. 47: 1162. 
https://www.ncbi.nlm.nih.gov/pubmed/34115458

293.Canter, D.J., et al. The International Penile Advanced Cancer Trial (InPACT): Rationale and Current Status. Eur Urol Focus, 2019. 5: 706. 
https://www.ncbi.nlm.nih.gov/pubmed/31160252

294.Hussein, A.M., et al. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer, 1990. 65: 433. 
https://www.ncbi.nlm.nih.gov/pubmed/2297633

295.Shammas, F.V., et al. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol, 1992. 147: 630. 
https://www.ncbi.nlm.nih.gov/pubmed/1538445

296.Leijte, J.A., et al. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol, 2007. 52: 488. 
https://www.ncbi.nlm.nih.gov/pubmed/17316964

297.Sharma, P., et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol, 2015. 33: 496 e17. 
https://www.ncbi.nlm.nih.gov/pubmed/26072110

298.Necchi, A., et al. Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. Clin Genitourin Cancer, 2016. 14: 518. 
https://www.ncbi.nlm.nih.gov/pubmed/27050716

299.Dhasthakeer, U., et al. Comparison of efficacy and toxicity of chemotherapeutic regimens used as adjuvant and/or neoadjuvant chemotherapy in penile cancer patients. Curr Probl Cancer, 2025. 55: 101185. 
https://www.ncbi.nlm.nih.gov/pubmed/39893772

300.An, X., et al. Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma. Cancer Cell, 2025. 43: 970. 
https://www.ncbi.nlm.nih.gov/pubmed/40215977

301.Necchi, A., et al. Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. Urol Oncol, 2019. 37: 531 e7. 
https://www.ncbi.nlm.nih.gov/pubmed/31053524

302.Raup, V., et al. Mp49-091397058899Adjuvant Chemotherapy in the Treatment of Lymph Node Positive Squamous Cell Carcinoma of the Penis: Analysis of the National Cancer Data Base. Journal of Urology, 2019. 201: e709. 
https://www.auajournals.org/doi/abs/10.1097/01.JU.0000556432.48421.1e

303.Paz Rojas, J.F., et al. Effectiveness and safety of adjuvant chemotherapy compared to neoadjuvant chemotherapy in patients with penile cancer and positive lymph nodes regarding overall survival and free disease survival: a systematic review and meta-analysis. Urol Oncol, 2022. 40: 200 e11. 
https://www.ncbi.nlm.nih.gov/pubmed/35307290

304.Patel, A., et al. Updates in the use of radiotherapy in the management of primary and locally-advanced penile cancer. Asian J Urol, 2022. 9: 389. 
https://www.ncbi.nlm.nih.gov/pubmed/36381600

305.Hakenberg, O.W., et al. EAU guidelines on penile cancer: 2014 update. Eur Urol, 2015. 67: 142. 
https://www.ncbi.nlm.nih.gov/pubmed/25457021

306.Robinson, R., et al. Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. Eur Urol, 2018. 74: 76. 
https://www.ncbi.nlm.nih.gov/pubmed/29703686

307.Chen, M.F., et al. Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan. World J Urol, 2004. 22: 60. 
https://www.ncbi.nlm.nih.gov/pubmed/14657999

308.Yuan, Z., et al. The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. World J Urol, 2018. 36: 1431. 
https://www.ncbi.nlm.nih.gov/pubmed/29589134

309.Jaipuria, J., et al. Adjuvant radiation compares favorably to chemotherapy in patients with carcinoma penis and nodal positivity restricted to groin. Urol Oncol, 2020. 38: 641 e9. 
https://www.ncbi.nlm.nih.gov/pubmed/32334927

310.Johnstone, P.A.S., et al. Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes. Eur Urol Focus, 2019. 5: 737. 
https://www.ncbi.nlm.nih.gov/pubmed/30327282

311.Ager, M., et al. Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. BJU Int, 2021. 128: 451. 
https://www.ncbi.nlm.nih.gov/pubmed/33249744

312.Tang, D.H., et al. Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. Urol Oncol, 2017. 35: 605 e17. 
https://www.ncbi.nlm.nih.gov/pubmed/28666722

313.Yuan, Z., et al. Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy. Rep Pract Oncol Radiother, 2019. 24: 593. 
https://www.ncbi.nlm.nih.gov/pubmed/31719799

314.Yuan, Z., et al. Radiation therapy in the management of the inguinal region in penile cancer: What’s the evidence? Urol Oncol, 2022. 40: 223. 
https://www.ncbi.nlm.nih.gov/pubmed/32482510

315.Winters, B.R., et al. Is there a benefit to adjuvant radiation in stage III penile cancer after lymph node dissection? Findings from the National Cancer Database. Urol Oncol, 2018. 36: 92 e11. 
https://www.ncbi.nlm.nih.gov/pubmed/29174944

316.Choo, R., et al. Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis? Minerva Urol Nefrol, 2020. 72: 474. 
https://www.ncbi.nlm.nih.gov/pubmed/31353875

317.Maibom, S.L., et al. DaPeCa-4: outcome in penile cancer patients with N3 disease due to extra nodal extension treated with surgery and chemo-irradiation. Scand J Urol, 2020. 54: 334. 
https://www.ncbi.nlm.nih.gov/pubmed/32734838

318.Haas, G.P., et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol, 1999. 161: 1823. 
https://www.ncbi.nlm.nih.gov/pubmed/10332445

319.Di Lorenzo, G., et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int, 2012. 110: E661. 
https://www.ncbi.nlm.nih.gov/pubmed/22958571

320.Zhang, S., et al. Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. Oncotarget, 2015. 6: 32212. 
https://www.ncbi.nlm.nih.gov/pubmed/26311739

321.Di Lorenzo, G., et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol, 2011. 60: 1280. 
https://www.ncbi.nlm.nih.gov/pubmed/21871710

322.Liu, W.K., et al. Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre. Journal of Clinical Urology, 2021. 16: 293. 
https://journals.sagepub.com/doi/abs/10.1177/20514158211025913

323.Wang, J., et al. Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes. Urology, 2015. 85: 1104. 
https://www.ncbi.nlm.nih.gov/pubmed/25819619

324.Noronha, V., et al. Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urol Ann, 2012. 4: 150. 
https://www.ncbi.nlm.nih.gov/pubmed/23248520

325.Bermejo, C., et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol, 2007. 177: 1335. 
https://www.ncbi.nlm.nih.gov/pubmed/17382727

326.Joshi, V.B., et al. Immune-based therapies in penile cancer. Nat Rev Urol, 2022. 19: 457. 
https://www.ncbi.nlm.nih.gov/pubmed/35851333

327.El Zarif, T., et al. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst, 2023. 115: 1605. 
https://www.ncbi.nlm.nih.gov/pubmed/37563779

328.Xiong, L., et al. First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study. J Natl Compr Canc Netw, 2024. 23. 
https://www.ncbi.nlm.nih.gov/pubmed/39705804

329.Yan, R., et al. First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer. BJU Int, 2023. 131: 198. 
https://www.ncbi.nlm.nih.gov/pubmed/35704436

330.Zhuang, T.Z., et al. Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution Experience. J Immunother Precis Oncol, 2025. 8: 1. 
https://www.ncbi.nlm.nih.gov/pubmed/39811423

331.Rouvinov, K., et al. Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience. J Pers Med, 2023. 13. 
https://www.ncbi.nlm.nih.gov/pubmed/38003938

332.Apolo, A.B., et al. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. J Clin Oncol, 2024. 42: 3033. 
https://www.ncbi.nlm.nih.gov/pubmed/38954785

333.McGregor, B.A., et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer, 2021. 127: 840. 
https://www.ncbi.nlm.nih.gov/pubmed/33216356

334.de Vries, H.M., et al. Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial. J Clin Oncol, 2023. 41: 4872. 
https://www.ncbi.nlm.nih.gov/pubmed/37487169

335.Garcia Del Muro, X., et al. Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study. Eur Urol Oncol, 2025. 8: 278. 
https://www.ncbi.nlm.nih.gov/pubmed/38749903

336.Cotait Maluf, F., et al. Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Advanced Penile Cancer: The Nonrandomized HERCULES (LACOG 0218) Clinical Trial. JAMA Oncol, 2025. 11: 1314. 
https://www.ncbi.nlm.nih.gov/pubmed/40965911

337.Brown, A., et al. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology, 2014. 83: 159. 
https://www.ncbi.nlm.nih.gov/pubmed/24238569

338.Carthon, B.C., et al. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int, 2014. 113: 871. 
https://www.ncbi.nlm.nih.gov/pubmed/24053151

339.Necchi, A., et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol, 2011. 29: e650. 
https://www.ncbi.nlm.nih.gov/pubmed/21632506

340.Necchi, A., et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int, 2018. 121: 348. 
https://www.ncbi.nlm.nih.gov/pubmed/28921872

341.Necchi, A., et al. Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study. Oncologist, 2022. 27: 1016. 
https://www.ncbi.nlm.nih.gov/pubmed/35881043

342.Lutz, S.T., et al. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol, 2014. 32: 2913. 
https://www.ncbi.nlm.nih.gov/pubmed/25113773

343.Brennan, J. Adjustment to cancer - coping or personal transition? Psychooncology, 2001. 10: 1. 
https://www.ncbi.nlm.nih.gov/pubmed/11180573

344.Horenblas, S., et al. Local recurrent tumour after penis-conserving therapy. A plea for long-term follow-up. Br J Urol, 1993. 72: 976. 
https://www.ncbi.nlm.nih.gov/pubmed/8306171

345.Branney, P., et al. The feasibility of patient reported outcome measures for the care of penile cancer. International Journal of Urological Nursing, 2021. 16: 138. 
https://onlinelibrary.wiley.com/doi/abs/10.1111/ijun.12307

346.Adegboye, O., et al. The Development and Feasibility of a Novel Electronic Patient-Reported Outcome Measures (Eproms) Questionnaire in patients with penile cancer. Clin Genitourin Cancer, 2024. 22: 102168. 
https://www.ncbi.nlm.nih.gov/pubmed/39117530

347.Ager, M., et al. Mp49-151397058899Surveillance Ct Algorithm for Node Positive Squamous Cell Carcinoma of the Penis. Journal of Urology, 2019. 201: e711. 
https://www.auajournals.org/doi/abs/10.1097/01.JU.0000556430.71291.09

348.Arora, A., et al. Patterns of recurrence in penile cancer: Implications for surveillance strategies. European Urology, 2022. 81: S1033. 
https://www.sciencedirect.com/science/article/pii/S0302283822007746

349.Chakiryan, N.H., et al. Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. J Urol, 2021. 206: 960. 
https://www.ncbi.nlm.nih.gov/pubmed/34032492

350.Vreeburg, M.T.A., et al. Evaluating follow-up in patients with lymph node-negative penile cancer at a high-volume centre. BJU Int, 2025. 136: 675. 
https://www.ncbi.nlm.nih.gov/pubmed/40551380

351.Fazili, A., et al. Early postoperative visits improve outcomes in inguinal lymph node dissection for penile cancer. BJU Int, 2025. 136: 289. 
https://www.ncbi.nlm.nih.gov/pubmed/40318206

352.Pang, K.H., et al. Outcomes of penile sarcomatoid squamous cell carcinoma from a single tertiary referral centre: a matched cohort study. BJU Int, 2023. 132: 337. 
https://www.ncbi.nlm.nih.gov/pubmed/37169730

353.Parnham, A.S., et al. Glansectomy and Split-thickness Skin Graft for Penile Cancer. Eur Urol, 2018. 73: 284. 
https://www.ncbi.nlm.nih.gov/pubmed/27746062

354.Djajadiningrat, R.S., et al. Ultrasound examination and fine needle aspiration cytology-useful for followup of the regional nodes in penile cancer? J Urol, 2014. 191: 652. 
https://www.ncbi.nlm.nih.gov/pubmed/23994372

355.Branney, P., et al. Mortality and sexuality after diagnosis of penile cancer: a participative study. International Journal of Urological Nursing, 2015. 10: 137. 
https://onlinelibrary.wiley.com/doi/abs/10.1111/ijun.12106

356.Ayres, B.E. Psychosocial Impact of Penile Cancer: An Unmet Need. Urol Clin North Am, 2024. 51: 327. 
https://www.ncbi.nlm.nih.gov/pubmed/38925735

357.Simpson, W.G., et al. Analysis of Suicide Risk in Patients with Penile Cancer and Review of the Literature. Clin Genitourin Cancer, 2018. 16: e257. 
https://www.ncbi.nlm.nih.gov/pubmed/29126815

358.Keeley, V., et al. A quality of life measure for limb lymphoedema (LYMQOL) J. Lymphoedema,
2010. 5: 26. 
https://eprovide.mapi-trust.org/instruments/lymqol

359.Rosen, R.C., et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology, 1997. 49: 822. 
https://www.ncbi.nlm.nih.gov/pubmed/9187685

360.Ware, J.E., et al., Conceptualization and Measurement of Health for Adults in the Health Insurance Study: Vol. I, Model of Health and Methodology. 1980, Santa Monica, CA. 
https://www.rand.org/pubs/reports/R1987z1.html

361.European Organisation for Research and Treatment of Cancer (EORTC). EORTC QLQ-C30 (version 3). 2018. 2022. 
https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf

362.Draeger, D.L., et al. Cross-Sectional Patient-Reported Outcome Measuring of Health-Related Quality of Life With Establishment of Cancer- and Treatment-Specific Functional and Symptom Scales in Patients With Penile Cancer. Clin Genitourin Cancer, 2018. 16: e1215. 
https://www.ncbi.nlm.nih.gov/pubmed/30201215

363.Zigmond, A.S., et al. The hospital anxiety and depression scale. Acta Psychiatr Scand, 1983. 67: 361. 
https://www.ncbi.nlm.nih.gov/pubmed/6880820

364.Bigelow, D.A., et al. Quality of life of community mental health program clients: validating a measure. Community Ment Health J, 1991. 27: 43. 
https://www.ncbi.nlm.nih.gov/pubmed/2019098

365.Herbenick, D., et al. The development and validation of the Male Genital Self-Image Scale: results from a nationally representative probability sample of men in the United States. J Sex Med, 2013. 10: 1516. 
https://www.ncbi.nlm.nih.gov/pubmed/23551571

366.Romero, F.R., et al. Sexual function after partial penectomy for penile cancer. Urology, 2005. 66: 1292. 
https://www.ncbi.nlm.nih.gov/pubmed/16360459

367.D’Ancona, C.A., et al. Quality of life after partial penectomy for penile carcinoma. Urology, 1997. 50: 593. 
https://www.ncbi.nlm.nih.gov/pubmed/9338738

368.Kieffer, J.M., et al. Quality of life for patients treated for penile cancer. J Urol, 2014. 192: 1105. 
https://www.ncbi.nlm.nih.gov/pubmed/24747092

369.Ficarra, V., et al. General state of health and psychological well-being in patients after surgery for urological malignant neoplasms. Urol Int, 2000. 65: 130. 
https://www.ncbi.nlm.nih.gov/pubmed/11054029

370.Sosnowski, R., et al. Assessment of quality of life in patients surgically treated for penile cancer: Impact of aggressiveness in surgery. Eur J Oncol Nurs, 2017. 31: 1. 
https://www.ncbi.nlm.nih.gov/pubmed/29173821

371.Wan, X., et al. A Comparative study of two types of organ-sparing surgeries for early stage penile cancer: Wide local excision vs partial penectomy. Eur J Surg Oncol, 2018. 44: 1425. 
https://www.ncbi.nlm.nih.gov/pubmed/29656798

372.Skeppner, E., et al. Treatment-seeking, aspects of sexual activity and life satisfaction in men with laser-treated penile carcinoma. Eur Urol, 2008. 54: 631. 
https://www.ncbi.nlm.nih.gov/pubmed/18788122

373.Croghan, S.M., et al. Phallus Preservation in Penile Cancer Surgery: Patient-reported Aesthetic & Functional Outcomes. Urology, 2021. 152: 60. 
https://www.ncbi.nlm.nih.gov/pubmed/33600836

374.Opjordsmoen, S., et al. Quality of life in patients treated for penile cancer. A follow-up study. Br J Urol, 1994. 74: 652. 
https://www.ncbi.nlm.nih.gov/pubmed/7827818

375.Gulino, G., et al. Sexual outcomes after organ potency-sparing surgery and glans reconstruction in patients with penile carcinoma. Indian J Urol, 2013. 29: 119. 
https://www.ncbi.nlm.nih.gov/pubmed/23956513

376.Carver, B.S., et al. Squamous cell carcinoma of the penis: a retrospective review of forty-five patients in northwest Louisiana. South Med J, 2002. 95: 822. 
https://www.ncbi.nlm.nih.gov/pubmed/12190215

377.Lukowiak, T.M., et al. Mohs micrographic surgery for male genital tumors: Local recurrence rates and patient-reported outcomes. J Am Acad Dermatol, 2021. 84: 1030. 
https://www.ncbi.nlm.nih.gov/pubmed/33279645

378.Sansalone, S., et al. Sexual outcomes after partial penectomy for penile cancer: results from a multi-institutional study. Asian J Androl, 2017. 19: 57. 
https://www.ncbi.nlm.nih.gov/pubmed/26643562

379.Sosnowski, R., et al. Assessment of selected quality of life domains in patients who have undergone conservative or radical surgical treatment for penile cancer: an observational study. Sex Health, 2019. 16: 32. 
https://www.ncbi.nlm.nih.gov/pubmed/30532994

380.Sedigh, O., et al. Sexual function after surgical treatment for penile cancer: Which organ-sparing approach gives the best results? Can Urol Assoc J, 2015. 9: E423. 
https://www.ncbi.nlm.nih.gov/pubmed/26279710

381.Yang, J., et al. Glans-reconstruction with preputial flap is superior to primary closure for post-surgical restoration of male sexual function in glans-preserving surgery. Andrology, 2014. 2: 729. 
https://www.ncbi.nlm.nih.gov/pubmed/24923484

382.Morelli, G., et al. Glansectomy with split-thickness skin graft for the treatment of penile carcinoma. Int J Impot Res, 2009. 21: 311. 
https://www.ncbi.nlm.nih.gov/pubmed/19458620

383.O’Kane, H.F., et al. Outcome of glansectomy and skin grafting in the management of penile cancer. Adv Urol, 2011. 2011: 240824. 
https://www.ncbi.nlm.nih.gov/pubmed/21603193

384.Palminteri, E., et al. Aesthetic neo-glans reconstruction after penis-sparing surgery for benign, premalignant or malignant penile lesions. Arab J Urol, 2011. 9: 115. 
https://www.ncbi.nlm.nih.gov/pubmed/26579279

385.Li, J., et al. Organ-sparing surgery for penile cancer: complications and outcomes. Urology, 2011. 78: 1121. 
https://www.ncbi.nlm.nih.gov/pubmed/22054385

386.Preto, M., et al. Functional and Patient Reported Outcomes Following Total Glans Resurfacing. J Sex Med, 2021. 18: 1099. 
https://www.ncbi.nlm.nih.gov/pubmed/33935017

387.Monteiro, L.L., et al. Erectile function after partial penectomy for penile cancer. Int Braz J Urol, 2021. 47: 515. 
https://www.ncbi.nlm.nih.gov/pubmed/33620995

388.Crook, J.M., et al. Penile brachytherapy: results for 49 patients. Int J Radiat Oncol Biol Phys, 2005. 62: 460. 
https://www.ncbi.nlm.nih.gov/pubmed/15890588

389.Makarewicz, R., et al. Interstitial brachytherapy for penile cancer: the experience of Oncology Centre in Bydgoszcz. J Contemp Brachytherapy, 2010. 2: 157. 
https://www.ncbi.nlm.nih.gov/pubmed/27853477

390.Windahl, T., et al. Sexual function and satisfaction in men after laser treatment for penile carcinoma. J Urol, 2004. 172: 648. 
https://www.ncbi.nlm.nih.gov/pubmed/15247753

391.White, E., et al. Impact of lymphoedema on quality of life following radical lymph node dissection for penile cancer. Int J Surg, 2016. 36: 38. 
https://www.sciencedirect.com/science/article/pii/S1743919116303600?via%3Dihub

392.Correa, A.F., et al. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 2018. 199: 1238. 
https://www.ncbi.nlm.nih.gov/pubmed/29248557

393.The British Lymphology Society and the Lymphoedema Support Network. Guidelines on the Management of Cellulitis in Lymphoedema 2022. 
https://www.lymphoedema.org/wp-content/uploads/2025/09/management_cellulitis.pdf

394.Scaglioni, M.F., et al. Systematic review of lymphovenous anastomosis (LVA) for the treatment of lymphedema. Microsurgery, 2017. 37: 947. 
https://www.ncbi.nlm.nih.gov/pubmed/28972280

395.Jakobsen, J.K., et al. Centralization and Equitable Care in Rare Urogenital Malignancies: The Case for Penile Cancer. Eur Urol Focus, 2021. 7: 924. 
https://www.ncbi.nlm.nih.gov/pubmed/34593356

396.Chipollini, J., et al. National Trends and Predictors of Organ-sparing for Invasive Penile Tumors: Expanding the Therapeutic Window. Clin Genitourin Cancer, 2018. 16: e383. 
https://www.ncbi.nlm.nih.gov/pubmed/28967504

397.Jakobsen, J.K., et al. DaPeCa-2: Implementation of fast-track clinical pathways for penile cancer shortens waiting time and accelerates the diagnostic process--A comparative before-and-after study in a tertiary referral centre in Denmark. Scand J Urol, 2016. 50: 80. 
https://www.ncbi.nlm.nih.gov/pubmed/26271679

398.Kirrander, P., et al. Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival. BJU Int, 2016. 117: 287. 
https://www.ncbi.nlm.nih.gov/pubmed/25395083

399.Zhu, Y., et al. Important Therapeutic Considerations in T1b Penile Cancer: Prognostic Significance and Adherence to Treatment Guidelines. Ann Surg Oncol, 2019. 26: 685. 
https://www.ncbi.nlm.nih.gov/pubmed/30565040

400.Bada, M., et al. Adherence to the EAU guidelines on Penile Cancer Treatment: European, multicentre, retrospective study. J Cancer Res Clin Oncol, 2019. 145: 921. 
https://www.ncbi.nlm.nih.gov/pubmed/30825028

401.Pecoraro, A., et al. Impact of the Standardization of Penile Cancer Care on the Quality of Care, Outcomes, and Academic-driven Centralization in a Single eUROGEN Referral Center. Eur Urol Focus, 2024. 10: 57. 
https://www.ncbi.nlm.nih.gov/pubmed/37537111

402.Thuret, R., et al. A contemporary population-based assessment of the rate of lymph node dissection for penile carcinoma. Ann Surg Oncol, 2011. 18: 439. 
https://www.ncbi.nlm.nih.gov/pubmed/20839061

403.Anderson, S., et al. Penile cancer in Ireland - A national review. Surgeon, 2022. 20: 187. 
https://www.ncbi.nlm.nih.gov/pubmed/34034967

404.Mistretta, F.A., et al. Adherence to Guideline Recommendations for Perioperative Chemotherapy in Patients with pN2-3 M0 Squamous Cell Carcinoma of the Penis: Temporal Trends and Survival Outcomes. Clin Oncol (R Coll Radiol), 2020. 32: e93. 
https://www.ncbi.nlm.nih.gov/pubmed/31706712

405.Ulvskog, E., et al. Nationwide Data Support Centralised Decision-making in Penile Cancer Care: A Before-and-After Study on Guideline Adherence and Disease-specific survival for Patients with an Indication for Perioperative Oncological Treatment. Eur Urol Open Sci, 2023. 51: 70. 
https://www.ncbi.nlm.nih.gov/pubmed/37187721

406.Ayres, B.E., et al. 50 Has centralisation of penile cancer services in the United Kingdom improved survival? European Urology Supplements, 2014. 13: e50. 
https://www.sciencedirect.com/science/article/pii/S156990561460052X